Results 111 to 120 of about 3,657 (192)

Timing is everything for compassionate use of delamanid [PDF]

Nature Medicine, 2015
openaire   +2 more sources

Curated Cases from the TB Expert Network: Unplugged!: Navigating Uncertainty in Treatment of a Child with Multidrug-Resistant Tuberculosis. [PDF]

J Clin Tuberc Other Mycobact Dis
Gaensbauer J, Harrison E, Wendorf K, Armitige L, Corriveau E, Haley CA, Weld ED, Chen L, Ramesh V, Goswami N.   +9 more
europepmc   +1 more source

Rifampicin-resistant TB in paediatrics: a patient series from a secondary health facility in Northern Malawi. [PDF]

Public Health Action
Chitsulo S, Omotayo D, Furin J, Saidi Y, Chisale M, Mbakaya B, Sinyiza F, Mwenyenkulu T.   +7 more
europepmc   +1 more source

Interim efficacy and safety analysis of the regimen containing delamanid in the treatment of multidrug resistant/rifampicin-resistant/extensively drug-resistant tuberculosis: a single-arm, prospective, monocentric, observational study. [PDF]

BMC Infect Dis
Qin Y, Chen Y, Cai Q.
europepmc   +1 more source

Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case report. [PDF]

JAC Antimicrob Resist
Klingmüller A, Zuber S, Hoffmann AM, Köhler N, Suárez I, Preßel T, Niemann S, Dreyer V, Decosterd LA, Choong E, Schütz B, Friesen I, Rybniker J.   +12 more
europepmc   +1 more source

A Prospective Cohort Study on the Usage, Safety, and Efficacy of Delamanid in Patients With Pulmonary Multidrug-Resistant Tuberculosis in South Korea. [PDF]

Open Forum Infect Dis
Mok J, Seo H, Cho Y, Lee T, Kim SH, Park HK, Oh JY, Shim TS.   +7 more
europepmc   +1 more source

Emergence of dual bedaquiline and linezolid resistance during treatment of pre-extensively drug-resistant tuberculosis: A case report from Zambia. [PDF]

IDCases
Kalaba D, Tembo D, Mbulo J, Mununga K, Twaambo L, Mutambo W.   +5 more
europepmc   +1 more source

Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation

Bedaquiline and delamanid are two drugs approved to treat drug-resistant tuberculosis, and each have been associated with QTc prolongation. We aimed to investigate the relationships between the drugs’ plasma concentrations and observed QTcF prolongation ...
Morganroth, Joel,, Tanneau, Lénaïg,, Shenje, Justin,, Dooley, Kelly E,, Svensson, Elin,, Maartens, Gary,, Upton, Caryn M,, Rosenkranz, Susan L,, Karlsson, Mats,, Cramer, Yoninah S,, Diacon, Andreas H,   +10 more
core  

Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women. [PDF]

Antimicrob Agents Chemother
Bruning-Barry R, Ambroso JL, Yang X, Hickman D, Harkins AM, Noble M, Paris M, Foraida S, Sun E, Beumont M.   +9 more
europepmc   +1 more source

Current and emerging therapies for pulmonary tuberculosis in adults. [PDF]

BMJ Med
Mahmood A, Ashfaq MB, Drain C, Melby E, Hunter M, Shaw TD.   +5 more
europepmc   +1 more source